title: IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function.
abstract: BACKGROUND
  Chronic treatment of mesangial cells with insulin-like growth factor-1 (IGF-1) results in intracellular lipid accumulation. These mesangial cells resemble foam cells.
  
  
  METHODS
  To determine whether this phenotype affects cell function, lipid-laden mesangial cells were tested for their ability to migrate in response to IGF-binding protein-5 (IGFBP-5) and to contract in response to angiotensin II (Ang II). IGFBP-5 binding and subsequent activation of the signal transduction cascade for migration were examined. To confirm that lipid accumulation was responsible for impaired contractility, lipid was removed from lipid-laden mesangial cells and the cells were re-tested for contractile response to Ang II.
  
  
  RESULTS
  In comparison to control mesangial cells, lipid-laden cells failed to migrate in response to IGFBP-5. Although cellular binding of IGFBP-5 was not altered by lipid accumulation, IGFBP-5 failed to activate cdc42, a Rho GTPase required for IGFBP-5-mediated mesangial cell migration. These data indicate that lipid accumulation within the mesangial cell interferes with the signal transduction response to IGFBP-5. In addition, mesangial cells treated with IGF-1 had reduced contraction to Ang II. When lipid accumulation was exaggerated by adding cholesteryl esters to the culture medium, mesangial cells failed to contract in response to Ang II. Following removal of excess lipid from these mesangial cells, the contractile response to Ang II was restored.
  
  
  CONCLUSIONS
  IGF-1 induces lipid accumulation in mesangial cells, which impairs their ability to respond to specific migratory and contractile stimuli. These observations are relevant to understanding functional abnormalities in diseases where mesangial foam cells occur, such as focal and segmental glomerulosclerosis and diabetic nephropathy.
authors.affiliation: Division of Nephrology, Department of Medicine, Veteran Affairs Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, USA.
authors.forename: Anne K
authors.initials: AK
authors.lastname: Berfield
authors.forename: Dennis L
authors.initials: DL
authors.lastname: Andress
authors.forename: Christine K
authors.initials: CK
authors.lastname: Abrass
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D002465:Cell Movement / Q000502:physiology*; D002478:Cells, Cultured; D005920:Glomerular Mesangium / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000378:metabolism / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D050356:Lipid Metabolism; D051381:Rats; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D020764:cdc42 GTP-Binding Protein / Q000378:metabolism
chemical_list: D018975:Insulin-Like Growth Factor Binding Protein 5; D007457:Iodine Radioisotopes; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D007334:Insulin-Like Growth Factor I; D020764:cdc42 GTP-Binding Protein